GSK de­clares a big win with pos­i­tive topline re­sults for its adult RSV vac­cine. But the ju­ry's still out on bot­tom line ef­fi­ca­cy

Em­ma Walm­s­ley’s bet on mak­ing GSK a pure play Big Phar­ma in­no­va­tor just cleared a ma­jor mile­stone. But the GSK team is not home free yet.

The glob­al play­er an­nounced that its adult RSV vac­cine cleared a Phase III tri­al — AReSVi 006 — of­fer­ing “ex­cep­tion­al pro­tec­tion” to 25,000 en­rollees over the age of 60, set­ting up a planned roll­out with reg­u­la­tors. But while GSK cheered this as a clear suc­cess, and a land­mark first, it’s keep­ing the key fig­ure on ef­fi­ca­cy in pre­vent­ing se­vere in­fec­tions un­der wraps for now, leav­ing the next big ques­tion of how this will look to reg­u­la­tors and in­dus­try ri­vals still unan­swered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER